The role of association of ADRB2 gene polymorphism with therapeutic response to β2-agonists in children with recurrent bronchial obstruction

Abstract

Background. The study of the effect of drugs at the molecular genetic level in the recurrent course of bronchial obstruction (RBО) in children improved the understanding of the pathogenesis of the disease and made it possible to better characterize the reliability of use in therapy. The aim of the study was to assess the clinical significance of the polymorphism of the Arg16Gly loci of the ADRB2 gene with a therapeutic response to β2-agonists in children with RBО of Uzbek ethnicity. Materials and methods. Tested 88 patients aged 6 to 15 years with recurrent bronchial obstruction and bronchial asthma with the polymorphism of the ADRB2 gene loci and determined the effectiveness of salbutamol in these groups of patients. Results. Results of the study of the significance of the polymorphism of the Arg16Gly locus of the ADRB2 gene with a therapeutic response to β2-agonists in children with RBO showed high efficacy of salbutamol in 72.9 % of children, among whom representatives of the A/G and A/A genotypes were found in the largest number. At the same time, the low efficacy of salbutamol was found in the greatest amount in carriers of the mutational genotype G/G of the Arg16Gly locus of the ADRB2 gene. Conclusions. The predictor role of the polymorphic locus rs1042713 (Arg16Gly) was determined in carriers of the unfavorable 46G allele of the G/G genotype of the ADRB2 gene, which was a genetic marker of children’s predisposition to RBO and BA in children. Children with the G/G genotype of the Arg16Gly locus of the ADRB2 gene are at risk for severe RBO and BA in children. Children with RBO carriers (Arg16Gly) of the homozygous G/G genotype have a high incidence of RBO recurrence against the background of ARVI and are at risk of developing BA.

Keywords

• bronchitis
• obstruction
• adrb2 gene
• β2-agonists
• children